Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 -- Amarin Corporation plc today announced the acceptance of funded research for presentation at the European Society of Cardiology Congress,...

Related Keywords

Sweden ,New Jersey ,United States ,Canada ,Switzerland ,Ireland ,Finland ,Lisbon ,Lisboa ,Portugal ,Lebanon ,United Arab Emirates ,Amsterdam ,Noord Holland ,Netherlands ,Dublin ,American ,Pascalm Burger ,Gabriel Steg ,Coll Cardiol ,Handrean Soren ,Johnr Nelson ,Michael Miller ,Peterp Toth ,Nabil Abadir ,Jannickan Dorresteijn ,Deepakl Bhatt ,Mark Marmur ,Clin Cardiol ,Amarin Pharmaceuticals Ireland ,Nasdaq ,Drug Administration ,Exchange Commission ,Amarin Corporation ,Journal Of The American College Cardiology ,Corporate Communications ,American Heart Association ,European Union ,European Society Of Cardiology ,A Report From The American Heart Association ,Head Of Global Medical Affairs ,European Society ,Mount Sinai Heart ,Valentin Fuster Professor ,Cardiovascular Medicine ,Arachidonic Acid ,Triglyceride Levels Mediate Most ,Icosapent Ethyl ,Szarek Phd ,Results From ,Science Box ,Sectional Analysis ,Clinical Characteristics ,Patients Using Icosapent ,Chief Medical Officer ,Global Medical Affairs ,New England Journal ,American College ,United Arab ,Product Characteristics ,Private Securities Litigation Reform Act ,Securities Act ,Heart Disease ,Stroke Statistics ,Report From ,American Heart ,Cardiovascular Events ,Cardiovascular Risk Reduction ,Total Ischemic Events ,Markets ,